Evidence map›Paper›PMID 36125638›Full record

ArticleMacromolecular bioscience2022

ROS-Responsive Glycopolymeric Nanoparticles for Enhanced Drug Delivery to Macrophages.

Oluwaseyi T Shofolawe-Bakare, Judith U de Mel, Sushil K Mishra, Mehjabeen Hossain, Christine M Hamadani, Mercedes C Pride, Gaya S Dasanayake, Wake Monroe, Eric W Roth, Eden E L Tanner and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Macromolecular bioscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Antimicrobial Resistance inAntibiotics (Basel, Switzerland) · 2026
    Review
  2. Nanozyme-based therapies for inflammatory immune disorders: opportunities and challenges.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Immunomodulatory Effects ofAntioxidants (Basel, Switzerland) · 2025
    Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Oluwaseyi T Shofolawe-BakareDepartment of Chemical Engineering, University of Mississippi, University, MS, 38677, USA.
Judith U de MelDepartment of Biomedical Engineering, University of Mississippi, University, MS, 38677, USA.
Sushil K MishraDepartment of BioMolecular Sciences, University of Mississippi, University, MS, 38677, USA.
Mehjabeen HossainDepartment of BioMolecular Sciences, University of Mississippi, University, MS, 38677, USA.
Christine M HamadaniDepartment of Chemistry and Biochemistry, University of Mississippi, University, MS, 38677, USA.
Mercedes C PrideDepartment of Chemistry and Biochemistry, University of Mississippi, University, MS, 38677, USA.
Gaya S DasanayakeDepartment of Chemistry and Biochemistry, University of Mississippi, University, MS, 38677, USA.
Wake MonroeDepartment of Chemistry and Biochemistry, University of Mississippi, University, MS, 38677, USA.
Eric W RothChemistry of Life Processes Institute, Northwestern University, Evanston, IL, 60208, USA.
Eden E L TannerDepartment of Chemistry and Biochemistry, University of Mississippi, University, MS, 38677, USA.
Robert J DoerksenDepartment of BioMolecular Sciences, University of Mississippi, University, MS, 38677, USA.
Adam E SmithDepartment of Chemical Engineering, University of Mississippi, University, MS, 38677, USA.
Thomas A WerfelDepartment of Chemical Engineering, University of Mississippi, University, MS, 38677, USA.ORCID 0000-0002-6005-1243
University of Mississippi · USJackson Memorial Hospital · USNorthwestern University · US

Funding

Tracking Glycosylation State with Fluorinated Glycosides ProbesP20GM130460 · NIGMS · UNIVERSITY OF MISSISSIPPI · PI Joshua S Sharp · 2020 to 2026
$17.9M
Laser spectroscopic instrumentation for isotopic sensing of biogenic Nitric OxideR21GM103460 · NIGMS · PRINCETON UNIVERSITY · PI WYSOCKI, GERARD · 2012 to 2012
$190k
NIGMS NIH HHS P20 GM130460NIGMS NIH HHS R21 GM103460
6 · The paper itself

Abstract

Macrophages play a diverse, key role in many pathologies, including inflammatory diseases, cardiovascular diseases, and cancer. However, many therapeutic strategies targeting macrophages suffer from systemic off-target toxicity resulting in notoriously narrow therapeutic windows. To address this shortcoming, the development of poly(propylene sulfide)-b-poly(methacrylamidoglucopyranose) [PPS-b-PMAG] diblock copolymer-based nanoparticles (PMAG NPs) capable of targeting macrophages and releasing drug in the presence of reactive oxygen species (ROS) is reported. PMAG NPs have desirable physicochemical properties for systemic drug delivery, including slightly negative surface charge, ≈100 nm diameter, and hemo-compatibility. Additionally, due to the presence of PPS in the NP core, PMAG NPs release drug cargo preferentially in the presence of ROS. Importantly, PMAG NPs display high cytocompatibility and are taken up by macrophages in cell culture at a rate ≈18-fold higher than PEGMA NPs-NPs composed of PPS-b-poly(oligoethylene glycol methacrylate). Computational studies indicate that PMAG NPs likely bind with glucose transporters such as GLUT 1/3 on the macrophage cell surface to facilitate high levels of internalization. Collectively, this study introduces glycopolymeric NPs that are uniquely capable of both receptor-ligand targeting to macrophages and ROS-dependent drug release and that can be useful in many immunotherapeutic settings.

Indexed as

Drug Delivery SystemsNanoparticlesMacrophagesPolymersReactive Oxygen SpeciesPolymersReactive Oxygen Speciesglycopolymerimmunotherapymacrophagesreactive oxygen species

Identifiers

PMID36125638
PMCPMC10013198
OpenAlexW4297459371

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.